Systemic administration of checkpoint blockade has reportedly generated immune related adverse events in patients and therefore to circumvent this issue, Rafiq et al. [99] engineered CART cells to secrete PD1 blocking scFv which demonstrated improved antitumor activity and persistence at the tumor site thereby evading from systemic immune toxicities. Here, PDCD1 is linked to neoplasm.